首页> 外文OA文献 >Increasing Prevalence of Vancomycin-Resistant Enterococcus faecium, Expanded-Spectrum Cephalosporin-Resistant Klebsiella pneumoniae, and Imipenem-Resistant Pseudomonas aeruginosa in Korea: KONSAR Study in 2001
【2h】

Increasing Prevalence of Vancomycin-Resistant Enterococcus faecium, Expanded-Spectrum Cephalosporin-Resistant Klebsiella pneumoniae, and Imipenem-Resistant Pseudomonas aeruginosa in Korea: KONSAR Study in 2001

机译:在韩国,耐万古霉素的粪肠球菌,耐广谱头孢菌素的肺炎克雷伯氏菌和耐亚胺培南的铜绿假单胞菌的患病率上升:2001年的KONSAR研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The 5th year KONSAR surveillance in 2001 was based on routine test data at 30 participating hospitals. It was of particular interest to find a trend in the resistances of enterococci to vancomycin, of Enterobacteriaceae to the 3rd generation cephalosporin and fluoroquinolone, and of Pseudomonas aeruginosa and acinetobacters to carbapenem. Resistance rates of Gram-positive cocci were: 70% of Staphylococcus aureus to oxacillin; 88% and 16% of Enterococcus faecium to ampicillin and vancomycin, respectively. Seventy-two percent of pneumococci were nonsusceptible to penicillin. The resistance rates of Enterobacteriaceae were: Escherichia coli, 28% to fluoroquinolone; Klebsiella pneumoniae, 27% to ceftazidime, and 20% to cefoxitin; and Enterobacter cloacae, ≥40% to cefotaxime and ceftazidime. The resistance rates of P. aeruginosa were 21% to ceftazidime, 17% to imipenem, and those of the acinetobacters were ≥61% to ceftazidime, aminoglycosides, fluoroquinolone and cotrimoxazole. Thirty-five percent of non-typhoidal salmonellae were ampicillin resistant, and 66% of Haemophilus influenzae were β-lactamase producers. Notable changes over the 1997-2001 period were: increases in vancomycin-resistant E. faecium, and amikacin- and fluoroquinolone-resistant acinetobacters. With the increasing prevalence of resistant bacteria, nationwide surveillance has become more important for optimal patient management, for the control of nosocomial infection, and for the conservation of the newer antimicrobial agents.
机译:2001年对KONSAR进行的第5年监视是基于30家参与医院的常规测试数据。特别令人感兴趣的是发现肠球菌对万古霉素,肠杆菌科细菌对第三代头孢菌素和氟喹诺酮,铜绿假单胞菌和不动杆菌对碳青霉烯类耐药的趋势。革兰氏阳性球菌的耐药率为:金黄色葡萄球菌对奥沙西林的耐药率为70%;粪肠球菌中分别有88%和16%的氨苄西林和万古霉素。百分之七十二的肺炎球菌对青霉素不敏感。肠杆菌科的耐药率是:大肠杆菌,对氟喹诺酮的耐药率为28%;对氟喹诺酮的耐药率为28%。肺炎克雷伯菌,头孢他啶占27%,头孢西丁占20%;阴沟肠杆菌:头孢噻肟和头孢他啶的含量≥40%。铜绿假单胞菌对头孢他啶的耐药率是21%,对亚胺培南的耐药率是17%,而不动杆菌对头孢他啶,氨基糖苷类,氟喹诺酮和cotrimoxazole的耐药率≥61%。 35%的非伤寒沙门氏菌对氨苄西林耐药,66%的流感嗜血杆菌是β-内酰胺酶生产者。 1997-2001年期间的显着变化是:耐万古霉素的粪肠球菌,耐阿米卡星和对氟喹诺酮的不动杆菌增加。随着耐药菌的流行,全国范围内的监视对于优化患者管理,控制医院感染以及保存新的抗菌剂变得越来越重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号